Prognostic factors for invasive aspergillosis in patients with haematological malignancies
- 1 January 2009
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 41 (6-7) , 483-490
- https://doi.org/10.1080/00365540902856529
Abstract
Reliable data defining risk factors for invasive aspergillosis (IA) in haematological patients are limited. Analysis of factors influencing IA-associated death is especially valuable in the light of recent progress in managing IA. Between 1997 and 2005 we evaluated factors influencing IA-attributable mortality. For univariate analyses we used Wilcoxon and log-rank test, and for multivariate analysis a Cox model of logistic backward regression was applied. Attributable mortality was 41% after 1 y. 50% of attributable deaths occurred within 6 weeks after IA diagnosis. Various parameters significantly correlated with death after IA: 1) uncontrolled malignancy (p =0.007); 2) extrapulmonary disease (p =0.0003); 3) stable disease, mixed response or progressive disease at first radiological evaluation (p =0.004); 4) proven IA (p =0.02); 5) IA > 110 d after PBSCT (p =0.0112). Prolonged duration of neutropenia was associated with increased mortality (p =0.0001). We observed a trend towards improved survival of IA during recent y (2003–2005). In a multivariate analysis, factors independently associated with attributable mortality included y of first diagnosis (p =0.0492), extrapulmonary IA (p =0.0353) and duration of neutropenia (p =0.0088). In conclusion, the identified risk factors may serve for the definition of high-risk situations. In these settings, increased efforts of prevention, early diagnosis and aggressive treatment of IA are warranted in order to improve survival.Keywords
This publication has 20 references indexed in Scilit:
- Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practiceExpert Opinion on Pharmacotherapy, 2008
- Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2008
- Improving outcomes of acute invasive Aspergillus rhinosinusitis n patients with hematologici malignancies or aplastic anemia: the role of voriconazoleHaematologica, 2008
- Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hostsJournal of Infection, 2007
- Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host DiseaseNew England Journal of Medicine, 2007
- Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with NeutropeniaNew England Journal of Medicine, 2007
- Comparison of Epidemiological, Clinical, and Biological Features of Invasive Aspergillosis in Neutropenic and Nonneutropenic Patients: A 6‐Year SurveyClinical Infectious Diseases, 2006
- Efficacy and Safety of Voriconazole in the Treatment of Acute Invasive AspergillosisClinical Infectious Diseases, 2002
- Defining Opportunistic Invasive Fungal Infections in Immunocompromised Patients with Cancer and Hematopoietic Stem Cell Transplants: An International ConsensusClinical Infectious Diseases, 2002
- Survival and Prognostic Factors of Invasive Aspergillosis After Allogeneic Bone Marrow TransplantationClinical Infectious Diseases, 1999